Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model (scientific article published on 16 July 2019)

The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

Q46711684

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Q50650208

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

Q50856021

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

Q52909973

Markov models in medical decision making: a practical guide.

Q53676269

Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Q53685592

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan

Q59349762

FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

Q62658359

Interferon therapy prolonged life expectancy among chronic hepatitis C patients

Q74531625

EASL Recommendations on Treatment of Hepatitis C 2018

Q88344766

Management of hepatocellular carcinoma: An update

Q27860530

Management of hepatocellular carcinoma

Q29616230

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Q29619974

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Q30250088

The natural history of hepatitis C virus infection: host, viral, and environmental factors

Q33974693

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

Q34044333

Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma

Q34210742

Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study

Q36000989

Hepatocellular carcinoma: epidemiology, risk factors, and screening

Q36140282

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

Q37112127

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

Q38462606

Markov models of natural history

Q39654812

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.

Q40434252

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2.

Q40791531

APASL consensus statements and recommendation on treatment of hepatitis C.

Q42400012

The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses

Q42977314

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death

Q42983596

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

Q42985646

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

Q42993140

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

Q42993893

Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study

Q42996072

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

Q42999252

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

Q44151781

Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis

Q44521773

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Q44527614

Clinical outcomes after transfusion-associated hepatitis C.

Q44746801

The long-term pathological evolution of chronic hepatitis C.

Q44765507

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

Q44920531

Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus

Q45073465

Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus

Q45370788

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

Q45414516

Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan

Q45420484

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

Q45737816

P433

issue

P921

main subject

Markov chain

Q176645

Hepatitis C virus

Q708693

P304